• The global industry was valued at US$ 1.6 Bn in 2023
• It is expected to grow at a CAGR of 5.2% from 2024 to 2034 and reach US$ 2.9 Bn by the end of 2034

Market Introduction

Attribute	Detail
Market Drivers	Rise in Incidence of Autism Spectrum Disorder Rise in Research-related Initiatives by Governments and Private Agencies

Regional Outlook

Attribute	Detail
Leading Region	North America

Autism Spectrum Disorder Treatment Market Snapshot

Attribute	Detail
Market Size in 2023	US$ 1.6 Bn
Market Forecast (Value) in 2034	US$ 2.9 Bn
Growth Rate (CAGR)	5.2%
Forecast Period	2024-2034
Historical Data Available for	2020-2022
Quantitative Units	US$ Bn for Value
Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape	Market share analysis by company (2023) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Market Segmentation	Drug Class Antipsychotic Drugs Selective Serotonin Reuptake Inhibitors Stimulants Sleep Medications Others Age Group Children Adults Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain China India Japan Australia & New Zealand Brazil Mexico South Africa GCC
Companies Profiled	Bristol-Myers Squibb Company Merck & Co., Inc. Novartis AG Eli Lilly and Company Pfizer Inc. Johnson & Johnson Otsuka Pharmaceutical Co., Ltd. Yamo Pharmaceuticals F. Hoffmann-La Roche Ltd. Axial Therapeutics, Inc. Curemark LLC Others
Customization Scope	Available Upon Request
Pricing	Available Upon Request

Autism Spectrum Disorder Treatment Market Report is Segmented by Drug Class (Antipsychotic Drugs, SSRIs/Antidepressants, Stimulants, Hormone Therapies and More), ASD Type (Autistic Disorder, Asperger's Sydrome, Rett Syndrome and More), Age Group (Pediatrics, Adolescents and More), Distribution Channel (Hospital Pharmacies, Retail and Drug Stores and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

The autism spectrum disorder management market is expected to reach approximately USD 2.4 billion in 2025 and expand to around USD 3.9 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.2% over the forecast period.

Metric	Value
Industry Size (2025E)	USD 2.4 Billion
Industry Value (2035F)	USD 3.9 Billion
CAGR (2025 to 2035)	5.2%

Country Wise Analysis

Country	CAGR (2025 to 2035)
United States	5.84%

Country	CAGR (2025 to 2035)
China	9.4%

Country	CAGR (2025 to 2035)
Germany	5.5%

Country	CAGR (2025 to 2035)
India	8.2%

Country	CAGR (2025 to 2035)
Brazil	6.8%

Competitive Outlook

Company Name	Estimated Market Share (%)
F. Hoffmann-La Roche Ltd	18-22%
Otsuka Pharmaceutical Co., Ltd.	14-18%
Johnson & Johnson (Janssen)	12-16%
Curemark LLC	8-12%
Quadrant Biosciences	5-9%

Explore Market Research Intellect's Autism Spectrum Disorder Treatment Market Report, valued at USD 5.5 billion in 2024, with a projected market growth to USD 9.2 billion by 2033, and a CAGR of 7.2% from 2026 to 2033.

The autism spectrum disorders market size was over USD 8.5 billion in 2024 and is estimated to reach USD 18.8 billion by the end of 2037, expanding at a CAGR of 7.1% during the forecast timeline, i.e., 2025-2037. North America industry is predicted to account for the largest share of 48.3% by 2037, owing to the continuous government investments in the region.

Autism Disorder Treatment Market is segmented By Drug Type (Anticonvulsants, Antipsychotics, and Others), and Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and e-Commerce)

The forecast for the global Autism Spectrum Disorder Treatment market predicts substantial growth, with market size projected to soar to USD 4.32 Billion by 2033, a significant increase from the USD 2.61 Billion recorded in 2024. This expansion reflects an impressive compound annual growth rate (CAGR) of 5.76% anticipated between 2025 and 2033.

The Global Autism Spectrum Disorder Treatment market

Uncover Market Research Intellect's latest Autism Disorder And Treatment Market Report, valued at USD 5.3 billion in 2024, expected to rise to USD 10.7 billion by 2033 at a CAGR of 8.4% from 2026 to 2033.

The global autism spectrum disorder treatment market is set to grow US$3.2 Bn by 2031, driven by awareness, early diagnosis, and personalized therapies

Key drivers for this market are: Rising Prevalence of Autism Disorder and Pervasive Developmental Disorder Have Fueled the Growth of the Market.(PDD) 24, Expected Approvals of Off-Label Drugs to Treat Autism Disorder Has Driven the Market Growth 25; Rising government or privately held societies taking initiatives to create the awareness about the disease 26. Potential restraints include: Weak Product Pipeline of First Drugs for Autism 27, Unknown Etiology and Pathophysiology of the Disorder Prevent Effective Treatment Options 28. Notable trends are: Increase in the prevalence of autism spectrum disorder (ASD) drive the market growth of Autism Disorder and Treatment..

The global autism diagnostic market is experiencing robust growth, driven by increasing prevalence of autism spectrum disorder (ASD), rising awareness, and advancements in diagnostic techniques. The market, currently valued at approximately $2.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 8% from 2025 to 2033, reaching an estimated market size of $4.8 billion by 2033. This expansion is fueled by several key factors. Improved diagnostic tools and early intervention programs are leading to earlier and more accurate diagnoses, thereby increasing the demand for diagnostic services. Furthermore, heightened public awareness and advocacy efforts are contributing to increased screening and diagnosis rates, particularly in developing economies. The market segmentation reveals a significant portion attributed to diagnostic services for Autistic Disorder and Asperger Syndrome, with Communication and Behavioral Therapy comprising a substantial share of therapeutic interventions. Geographic analysis reveals strong market presence in North America and Europe, owing to established healthcare infrastructure and high prevalence rates. However, the Asia-Pacific region is poised for significant growth due to rising awareness and increasing disposable incomes. Despite these positive market drivers, certain challenges persist. High costs associated with diagnostic assessments and specialized therapies remain a barrier, particularly in low- and middle-income countries. Variability in diagnostic criteria and practices across different regions presents another obstacle to consistent market growth. Furthermore, the availability of trained professionals specialized in autism diagnosis remains a bottleneck in several areas. Addressing these challenges through policy interventions, increased investment in research and development, and improved healthcare access will be crucial to achieving the full market potential. The competitive landscape is characterized by a mix of large pharmaceutical companies involved in drug development and smaller specialized companies focused on diagnostic tools and therapeutic interventions. The market's future is promising, driven by ongoing research into the causes and treatments of ASD, resulting in improved diagnostic precision and potentially more effective therapies.

Snapshot img

Autism Spectrum Disorder Therapeutics Market Size 2024-2028

The autism spectrum disorder therapeutics market size is forecast to increase by USD 766.1 million at a CAGR of 6.78% between 2023 and 2028.

The ASD therapeutics market is experiencing significant growth due to several key factors. The increasing prevalence of ASD, with an estimated 1 in 54 children diagnosed in the United States alone, is driving market expansion. Additionally, there is a growing emphasis on personalized medicine for the treatment of ASD, as each individual's symptoms and needs vary. 
However, the market is also subject to stringent regulations, ensuring the safety and efficacy of therapeutic interventions and medical technologies. These regulations, while necessary, can pose challenges for market growth. Overall, the ASD therapeutics market is poised for continued expansion, as researchers and healthcare professionals work to develop effective and personalized treatments for this complex disorder.

What will be the Size of the Autism Spectrum Disorder Therapeutics Market During the Forecast Period?

Request Free Sample

The market encompasses a range of medications and therapies designed to address the diverse needs of individuals diagnosed with autism spectrum disorders (ASD), including autistic disorder and Asperger's syndrome. This market is driven by the growing awareness and early diagnosis of ASD, fueled by increasing public education and advancements in genetic research and genetic testing. 
Antipsychotic drugs remain a significant component of the market, primarily used to manage aggressive behaviors, mood stabilization, and other behavioral symptoms. However, the landscape is evolving with the emergence of personalized therapies and innovative treatments, such as brain-based therapies and medications tailored to specific genetic mutations. Both pediatric and adult patients benefit from these advancements, with the age of diagnosis continuing to decrease for children.
The prevalence and diagnosis rate of ASD are on the rise, making this a dynamic and growing market.

How is this Autism Spectrum Disorder Therapeutics Industry segmented and which is the largest segment?

The autism spectrum disorder therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Distribution Channel

  Retail pharmacy
  Hospital pharmacy
  Online pharmacy


Type

  Stimulants
  Selective serotonin reuptake inhibitors
  Antipsychotic drugs
  Sleep medications
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Distribution Channel Insights

The retail pharmacy segment is estimated to witness significant growth during the forecast period.

The Autism Spectrum Disorder (ASD) therapeutics market is projected to expand significantly due to increasing awareness, early diagnosis, and innovative treatment approaches. Antipsychotic drugs, including bipolar disorder therapeutics, are commonly prescribed for managing aggressive behaviors, mood stabilization, and anxiety in ASD patients. Hospital pharmacies and drug stores serve as essential distribution channels for these medications. The market growth is influenced by the heterogeneity and symptom severity of ASD, requiring personalized therapies and targeted medications. Pediatric and adult patients benefit from behavioral therapies, including applied behavior analysis and speech therapy. Novel therapies, such as genetic insights, novel targeted therapies, and remote patient monitoring, are emerging as promising solutions.

The prevalence of ASD is higher in children, with early diagnosis typically occurring between the ages of 2 and 5, although it can affect individuals of all ethnicities. The complex underlying mechanisms of ASD necessitate continued drug development and approvals to address the diverse needs of patients. The market's geographic presence is expanding, with a focus on precision medicine and brain-based therapies for this genetic condition.

Get a glance at the Autism Spectrum Disorder Therapeutics Industry report of share of various segments Request Free Sample

The Retail pharmacy segment was valued at USD 880.70 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 38% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The Autism Spectrum Disorder (ASD) therapeutics market in North America is experiencing g

Global Autism Spectrum Disorders Treatment market size is expected to reach $4.11 billion by 2029 at 7.4%, surging prevalence of autism spectrum disorders drives market expansion

Get key insights from Market Research Intellect's Autism Spectrum Disorder (ASD) Treatment Market Report, valued at USD 3.8 billion in 2024, and forecast to grow to USD 7.5 billion by 2033, with a CAGR of 8.1% (2026-2033).

Report of Autism Spectrum Disorder (ASD) Treatment is covering the summarized study of several factors encouraging the growth of the market such as market size, market type, major regions and end user applications. By using the report customer can recognize the several drivers that impact and govern the market. The report is describing the several types of Autism Spectrum Disorder (ASD) Treatment Industry. Factors that are playing the major role for growth of specific type of product category and factors that are motivating the status of the market.

Autism Disorder and Treatment Market Outlook

The Autism Disorder and Treatment market size was valued at approximately USD 3.5 billion in 2023. Driven by increasing awareness and advancements in therapeutic interventions, this market is expected to witness a compound annual growth rate (CAGR) of 6.8% from 2024 to 2032, reaching an estimated valuation of USD 6.3 billion by the end of the forecast period. The growth trajectory is primarily fueled by the rising prevalence of autism spectrum disorders (ASD) globally, along with heightened research efforts to develop effective treatment options and a growing societal focus on mental health and neurodevelopmental disorders.

One of the primary growth factors driving the autism disorder and treatment market is the increasing prevalence of autism spectrum disorders across the globe. Autism, a complex neurodevelopmental disorder characterized by challenges in social interaction, communication, and repetitive behaviors, affects millions of individuals worldwide. With heightened awareness and better diagnostic capabilities, more cases are being identified, leading to a growing demand for effective treatment and management strategies. Additionally, the rise in autism prevalence has sparked significant interest in scientific and medical communities, driving research and development efforts towards innovative therapeutic options, thereby contributing to market growth.

Another significant growth factor is the advancements in technology and research, which have paved the way for new and improved treatment modalities for autism disorder. Breakthroughs in genetic research, neurology, and behavioral sciences have led to a deeper understanding of autism's underlying causes and mechanisms. As a result, targeted therapies and personalized medicine are gaining traction as they promise more effective and tailored treatment outcomes for individuals with autism. Furthermore, technological innovations such as digital health tools, teletherapy, and virtual reality therapies are transforming the landscape of autism treatment, offering new avenues for intervention and support, thus propelling market growth.

The increasing investment and funding in autism research and related healthcare infrastructure are also pivotal in driving market growth. Governments, non-profit organizations, and private entities are investing heavily in autism-related research, aiming to discover novel treatment options and improve existing therapies. These investments not only accelerate the development of effective treatments but also enhance the accessibility and availability of autism care services. Moreover, public-private partnerships and collaborations between healthcare providers, research institutions, and pharmaceutical companies are fostering a conducive environment for innovation and growth in the autism treatment market.

Regionally, the autism disorder and treatment market is witnessing notable growth across various geographies, with North America leading the charge due to its advanced healthcare infrastructure and robust research initiatives. However, the Asia Pacific region is expected to experience the fastest growth during the forecast period, driven by increasing awareness, improving healthcare access, and rising government initiatives to address autism. Other regions such as Europe and Latin America are also contributing to market expansion, buoyed by growing recognition of autism and efforts to enhance treatment strategies. Furthermore, efforts to destigmatize autism and provide inclusive environments are playing a crucial role in advancing the market across different regions.

Treatment Type Analysis

The treatment landscape for autism disorder is highly diverse, encompassing various approaches to manage symptoms and improve quality of life for individuals with autism. Behavioral approaches, such as Applied Behavior Analysis (ABA), are among the most widely used treatment modalities. ABA focuses on reinforcing positive behaviors and reducing negative or harmful behaviors through structured interventions and rewards. This approach has shown significant efficacy in improving communication, social skills, and adaptive behaviors in children with autism. The growing acceptance and success of behavioral therapies are contributing to the overall growth of the autism treatment market, as they are often recommended as first-line interventions for individuals across the autism spectrum.

Medication is another critical component of autism treatment, particularly for managing co-occurring conditions such as anxiety, depression, and attention deficit hyperactivi

The size of the Global Autism Spectrum Disorders Treatment Market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of > 7.00% during the forecast period.Autism Spectrum Disorders include all neurodevelopmental conditions defined by persistent deficits in social communication and social interaction combined with restricted, repetitive patterns of behavior, interests, or activities. ASD is the collective term for all disorders, whose manifestations vary in severity and complexity in one dimension.Treatments of ASD are to enhance the quality of life by taking care of the individual's needs and challenges. Though there is no cure for ASD, there are different interventions that can help control the symptoms and improve skills. Such interventions are often multidisciplinary in nature, with behavioral therapies, educational interventions, and in some cases, medication.Behavioural therapies, especially Applied Behaviour Analysis (ABA), can be used to teach new skills to reduce difficult behaviors and enable greater independence. Speech therapy can help improve communication skills in individuals with ASD, occupational therapy teaching daily living and sensory integration skills, and medications might be prescribed as a course of treatment when there is evidence of specific symptomatology like anxiety or aggression.It is very important that any intervention be done early for individuals with ASD because it may benefit them greatly in terms of improvement outcomes.Early diagnosis and application of appropriate therapies will surely help individuals with ASD to blossom to their full potential. Recent developments include: In August 2022, Bened Life released the first gut-brain medical probiotic, Neuralli. Made in the United States and utilizing the patented probiotic strain L. plantarum PS128, Neuralli is designed to promote mental health and support neurological conditions including but not limited to Parkinson's disease (PD) and autism spectrum disorder (ASD)., In March 2022, STALICLA, a Swiss clinical-stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), reported the highly successful completion of the phase 1b trials for its lead drug candidate STP1. These clinical data clear the way for the first application of STALICLA's precision medicine discovery platform in autism spectrum disorders.. Key drivers for this market are: Increasing Burden of Autism Spectrum Disorder (ASD) Worldwide, Rising Awareness Pertaining ASD and Growing Number of Investments. Potential restraints include: High Cost of Autism Spectrum Disorder Treatment and Diagnosis, Stringent Regulations Pertaining to Product Approval. Notable trends are: Autistic Disorder Segment is Expected to Hold a Major Market Share in the Autism Spectrum Disorders Treatment Market.

Global Autism Spectrum Disorder Treatment Market Report 2024 comes with the extensive industry analysis of development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2024-2030. The report may be the best of what is a geographic area which expands the competitive landscape and industry perspective of the market.

Snapshot img

Autism Spectrum Disorder Market Size 2025-2029

The autism spectrum disorder market size is forecast to increase by USD 3.44 billion at a CAGR of 7.6% between 2024 and 2029.

The market is experiencing significant growth due to several key factors. One of the primary drivers is the increasing prevalence of autism spectrum disorder (ASD), which has led to a higher demand for medications used to manage its symptoms. Focalin, Vyvanse, Ritalin, and other stimulant medications are commonly prescribed to help manage attention deficit and hyperactivity symptoms, while Abilify and Risperdal are often used to treat irritability and behavioral issues. For instance, artificial intelligence (AI)-based devices can help diagnose ASD by analyzing speech patterns and facial expressions.
Retail pharmacies and hospital pharmacies play crucial roles in the distribution of these medications. Partnerships and collaborations between healthcare providers, pharmacies, and manufacturers are also on the rise to improve access and patient care. However, a lack of awareness about ASD and its associated challenges can hinder market growth. Despite these challenges, the market is expected to continue expanding due to the increasing number of diagnoses and the ongoing development of new treatments.

What will be Autism Spectrum Disorder Market Size During the Forecast Period?

Request Free Sample

Neurodevelopmental disorders, including Autism Spectrum Disorder (ASD), Autistic Disorder, Asperger's Syndrome, Pervasive Development Disorder (PDD), and related conditions, pose significant challenges for individuals and their families. These disorders are characterized by communication deficits and social interaction difficulties. According to the World Health Organization (WHO), approximately 1 in 54 children in the US have been identified with ASD. The diagnosis and treatment of neurodevelopmental disorders, particularly ASD, have gained increasing attention in the health care sector. Early diagnosis and intervention are crucial to improve outcomes for individuals with ASD. Several treatment options are available, including Behavioral therapy, applied behavior analysis, medication, and early intervention programs. Behavioral therapy and applied behavior analysis are evidence-based interventions that have shown significant improvements in the development of social and communication skills in children with ASD. These therapies aim to teach new skills and modify existing ones through positive reinforcement and systematic instruction. The diagnostic process for neurodevelopmental disorders involves a comprehensive evaluation by healthcare professionals. Early diagnosis is essential to ensure timely intervention and improve long-term outcomes. However, the diagnostic process can be complex and time-consuming, requiring multiple assessments and consultations.
Advancements in biotechnology have led to the development of innovative devices and technologies to aid in the diagnosis and treatment of neurodevelopmental disorders. For instance, artificial intelligence (AI)-based devices can help diagnose ASD by analyzing speech patterns and facial expressions. Additionally, rare cannabinoids have shown promise in reducing symptoms associated with ASD. The treatment market for neurodevelopmental disorders, including ASD, is expected to grow due to the increasing awareness and availability of treatment options. According to a report by the Centers for Disease Control and Prevention (CDC), health care expenditures for children with ASD are approximately USD6,000 higher than those without ASD. Therapeutic medicines, such as Vraylar (cariprazine) and Rexulti (brexpiprazole), have shown efficacy in treating symptoms of neurodevelopmental disorders, including ASD. Clinical trials are ongoing to further evaluate the safety and effectiveness of these medications. Health care facilities play a critical role in the diagnosis, treatment, and care of individuals with neurodevelopmental disorders. These facilities offer a range of services, including diagnostic evaluations, therapy sessions, and support groups. The demand for these services is expected to increase as more individuals are diagnosed and seek treatment. In conclusion, the market for neurodevelopmental disorders, particularly ASD, is growing due to the increasing awareness and availability of treatment options.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Non-pharmacological therapies
  Pharmacological therapies


Age Group

  Pediatric
  Adult


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India

The global Autism Spectrum Disorders (ASD) Treatment market is experiencing robust growth, projected to maintain a Compound Annual Growth Rate (CAGR) exceeding 7% from 2025 to 2033. This expansion is fueled by several key factors. Increasing awareness and diagnosis rates of ASD are leading to higher demand for treatment options. Advancements in pharmaceutical research and development, particularly in novel drug classes like antipsychotics, SSRIs/antidepressants, and stimulants tailored to specific ASD symptoms, are significantly contributing to market growth. Furthermore, the rising prevalence of ASD globally, coupled with supportive government initiatives and increased healthcare expenditure in developed and developing nations, further bolster market expansion. The market is segmented by drug class (Antipsychotic Drugs, SSRIs/Antidepressants, Stimulants, Other Drug Classes), type of ASD (Autistic Disorder, Asperger's Syndrome, Other Types), and distribution channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies). North America currently holds a significant market share due to established healthcare infrastructure, high diagnostic rates, and robust pharmaceutical research activity. However, Asia-Pacific is expected to witness substantial growth in the coming years, driven by rising awareness, increasing disposable incomes, and expanding healthcare access. Competitive dynamics within the market are shaped by a mix of established pharmaceutical giants (like Otsuka Pharmaceutical Co Ltd, F Hoffmann-La Roche Ltd, Novartis AG) and emerging biotech companies (Q BioMed Inc, PaxMedica, Zynerba Pharmaceuticals Inc). These companies are engaged in intense research and development, focusing on innovative therapies to address unmet needs within the ASD treatment landscape. The market also faces some restraints, including high treatment costs, variable treatment response among individuals with ASD, and the need for ongoing research to better understand the complex etiology of ASD. Despite these challenges, the overall outlook remains positive, indicating substantial growth opportunities for companies engaged in ASD treatment development and distribution. The market's future trajectory will significantly depend on the success of new drug approvals, the expansion of access to treatment in underserved regions, and continued advancements in diagnostic techniques. Recent developments include: In August 2022, Bened Life released the first gut-brain medical probiotic, Neuralli. Made in the United States and utilizing the patented probiotic strain L. plantarum PS128, Neuralli is designed to promote mental health and support neurological conditions including but not limited to Parkinson's disease (PD) and autism spectrum disorder (ASD)., In March 2022, STALICLA, a Swiss clinical-stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), reported the highly successful completion of the phase 1b trials for its lead drug candidate STP1. These clinical data clear the way for the first application of STALICLA's precision medicine discovery platform in autism spectrum disorders.. Key drivers for this market are: Increasing Burden of Autism Spectrum Disorder (ASD) Worldwide, Rising Awareness Pertaining ASD and Growing Number of Investments. Potential restraints include: Increasing Burden of Autism Spectrum Disorder (ASD) Worldwide, Rising Awareness Pertaining ASD and Growing Number of Investments. Notable trends are: Autistic Disorder Segment is Expected to Hold a Major Market Share in the Autism Spectrum Disorders Treatment Market.